Hims & Hers Health's Strategic Expansion into Women's Health: Capturing the $24.35 Billion Menopause Care Market

The global perimenopause and menopause care sector is undergoing a seismic shift, driven by demographic trends, technological innovation, and a cultural reckoning with women's health. By 2025, over 1 billion women globally will be in menopause, representing 12% of the global population, according to a Grand View Research report. This demographic inevitability, coupled with a $17.79 billion market in 2024 projected to grow at a 5.42% CAGR to $24.35 billion by 2030, has positioned menopause care as one of the most lucrative opportunities in healthcare. Hims & Hers Health, a digital health pioneer, is capitalizing on this shift with a bold expansion into personalized menopause and perimenopause care, leveraging its telehealth infrastructure, AI-driven personalization, and a direct-to-consumer model to capture a significant share of this growing market.

Market Dynamics: A $40 Billion U.

S. Opportunity

The U.S. menopause market alone is forecasted to grow from $5.56 billion in 2024 to $8.58 billion by 2033, according to a Coherent Market Insights forecast, but the potential is even greater. According to a Boston Consulting Group report, if all women with moderate to severe menopause symptoms received adequate treatment, the U.S. market could expand eightfold to nearly $40 billion by 2030. This gap underscores a critical unmet need: only 30% of OB/GYN residency programs in the U.S. include menopause training, according to a Yahoo Finance article, leaving millions of women underserved. Hims & Hers is addressing this void by offering tailored treatment plans, including estradiol and progesterone in pill, patch, or cream forms, overseen by licensed providers trained in menopause care.

The company's strategy aligns with key market drivers. Dietary supplements and non-hormonal therapies currently dominate 94.23% of the global market, but telehealth and digital tools are rapidly gaining traction. Hims & Hers integrates these innovations, offering AI-powered symptom tracking, virtual consultations, and compounding pharmacies to deliver a seamless patient experience. This approach not only improves accessibility but also reduces costs—a critical factor in a sector where affordability is a barrier for many women, according to a PitchGrade analysis.

Competitive Positioning: A First-Mover Advantage

Hims & Hers is outpacing competitors by combining clinical expertise with a patient-centric model. While traditional telehealth providers like Teladoc Health and Roman focus on general wellness or male-specific care, Hims & Hers has carved a niche in women's health, a sector historically underserved by mainstream healthcare. Its platform now serves 2.4 million subscribers, according to an AlphaMonk Substack post, with the Hers brand driving growth in women's health categories such as hair loss and dermatology. The company's expansion into menopause care builds on this foundation, offering a holistic approach that includes mental health resources, nutritional guidance, and fitness support.

Customer adoption metrics further validate its appeal. A 2025 survey revealed that 94% of Hims & Hers users rated their telehealth experience as equal to or better than in-person visits, a testament to the platform's ease of use and clinical quality. This loyalty is critical in a market where trust and consistency are paramount. Additionally, Hims & Hers' AI-driven tool, MedMatch, enhances provider decision-making by analyzing patient data to recommend personalized treatment plans, as described in a Hims newsroom article, a differentiator in an industry still reliant on generalized protocols.

Financial Projections and Investment Potential

Hims & Hers' aggressive expansion is backed by ambitious financial goals. The company aims to reach $1 billion in annual revenue by 2026 and projects $2.3–$2.4 billion in 2025 revenue, driven by its menopause and perimenopause offerings. With the global market expected to grow at a 5.42% CAGR, the company is well-positioned to capture a disproportionate share of this growth. Analysts note that Hims & Hers' direct-to-consumer model, which bypasses traditional healthcare bottlenecks, allows for rapid scaling and higher margins compared to brick-and-mortar competitors.

However, risks remain. The menopause care sector is attracting new entrants, including startups focused on non-hormonal therapies and wearable technologies, and regulatory scrutiny of telehealth services could impact margins. Yet, Hims & Hers' first-mover advantage, robust customer base, and integration of AI and telehealth mitigate these risks.

Conclusion: A Lucrative Long-Term Bet

For investors, Hims & Hers Health represents a compelling opportunity to capitalize on the $24.35 billion menopause care market. Its strategic alignment with demographic trends, technological innovation, and unmet clinical needs positions it as a leader in a sector poised for exponential growth. As the company continues to expand its treatment options and refine its AI-driven personalization tools, it is likely to cement its dominance in women's health—a market that will only grow more critical in the coming decade.